Ancora Archives
Therapeutic Antibody Discovery and Development event is Jan. 23
Jan. 8, 2019—Vanderbilt's Center for Technology Transfer and Commercialization, the Vanderbilt Institute of Chemical Biology and Deerfield will bring together experts in discovery and development of antibody therapeutics Jan. 23 to discuss and review state-of-the-art developments in the field.
Therapeutic Antibody Discovery and Development event is Jan. 23
Jan. 2, 2019—Vanderbilt's Center for Technology Transfer and Commercialization, the Vanderbilt Institute of Chemical Biology and Deerfield will bring together experts in discovery and development of antibody therapeutics Jan. 23 to discuss and review state-of-the-art developments in the field.
Ancora announces major funding awards to support Vanderbilt drug discovery research
Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.
Slides can help faculty with Ancora proposal submissions
May. 10, 2018—The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals.
Ancora inaugural request for proposals announced
Apr. 20, 2018—The Office of the Vice Provost for Research and Deerfield Management announce the inaugural request for proposals for Ancora Innovation, LLC, with a due date of June 4. An RFP information session is scheduled from 2 to 3:30 p.m. Friday, April 27, at Sarratt Student Center, Room 325.
Deerfield Management, Vanderbilt University announce launch of Ancora Innovation
Mar. 28, 2018—Deerfield Management and Vanderbilt University announced March 28 the launch of Ancora Innovation, LLC (“Ancora”), a Deerfield company that will support Vanderbilt’s innovative life science research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development.